The US Food and Drug Administration’s biologics center is considering ways to streamline the development and regulatory review of genome editing technology targeted at different mutations of the same gene.
The Center for Biologics Evaluation and Research “is working on developing a guidance on genome editing technology under the platform framework,” Julie Tierney, deputy center director for strategy, policy and
Key Takeaways
-
CBER is developing guidance on how genome editing technology can leverage the platform framework.
-
The FDA could grant approval for treating all mutations in a single gene after the sponsor has demonstrated an effect on a few mutations, CBER’s Peter Marks says.
-
NCATS’ Philip “P.J
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?